drugset / Trial / NCT01450176
Comparing Patient Satisfaction With Pataday or Bepreve
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to compare patient satisfaction with Pataday (Olopatadine hydrochloride 0.2%) one daily (QD) and Bepreve (Bepotastine besilate ophthalmic solution 1.5%) two times a day (BID).
Timeline
- Start
- 2011-09
- Primary completion
- 2011-10
- Completion
- 2011-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bepotastine | Small molecule | 1.5 % | Other |
| Comparator | Olopatadine | Other / unclassified | 0.2 % | Other |